The Science of Psilocybin.
And Beyond.
Deep psilocybin neuroscience — receptor binding, neuroplasticity, clinical protocols, veteran restoration — plus research on other psychedelic compounds. Published daily. Every claim backed by peer-reviewed data.
Featured Articles
Ketamine vs DXM: The Neuroscience
Two non-competitive NMDA antagonists from opposite worlds — a hospital anesthetic and a cough syrup — both now FDA-approved antidepressant ingredients. Potency, CYP2D6, sigma-1, dissociation, 2026 status, and safety.
Harmala Alkaloids: The Neuroscience
Ayahuasca's other half. The beta-carbolines harmine, harmaline, and THH barely trip on their own — their real job is reversible MAO-A inhibition, the trick that makes oral DMT active. Plus harmine's surprising second life as a DYRK1A inhibitor.
MDMA vs LSD: The Neuroscience
Two serotonin drugs that work in opposite directions — MDMA reverses the transporter to flood the synapse; LSD presses the 5-HT2A receptor. Mechanism, experience, the neurotoxicity debate, 2026 clinical status, and the law.
Datura & Scopolamine: The Neuroscience
The nightshade deliriants and their tropane alkaloids — how scopolamine and atropine block acetylcholine to produce true delirium, the amnesia model behind Alzheimer’s research, the real medicines, and honest danger.
Cannabis vs Psilocybin: The Neuroscience
Two of the most famous mind-altering plants, two entirely different systems - THC's CB1 dampening versus psilocybin's 5-HT2A excitation. Mechanism, dependence, neuroplasticity, 2026 evidence, and the law.
Kanna (Sceletium tortuosum): The Neuroscience
How a fermented South African succulent calms the mind - the mesembrine alkaloids, a rare dual SERT and PDE4 mechanism, the amygdala-fMRI and cognition trials, and an honest, still-small evidence base.
Mescaline vs Psilocybin: The Neuroscience
Two of the oldest psychedelics, built on opposite chemical scaffolds, converge on one 5-HT2A doorway. Mechanism, potency, duration, 2026 trials, and an honest evidence asymmetry.
Kava (Kavalactones): The Neuroscience
The Pacific's ceremonial drink, explained: how kavalactones calm anxiety through a non-benzodiazepine GABA-A mechanism - the six kavalactones, the anxiety trials, and the hepatotoxicity controversy.
DMT vs 5-MeO-DMT: The Neuroscience
Chemical siblings that reach opposite ends of the psychedelic experience: 5-HT2A visions and entities vs 5-HT1A ego-dissolution and the void. Mechanism, dosing, 2026 trials, and risk.
PCP (Phencyclidine): The Neuroscience
The anesthetic that failed on the operating table became psychiatry's key to psychosis - and the ancestor of ketamine's antidepressant. Mechanism, the schizophrenia model, and honest harms.
Ibogaine vs Ketamine: The Neuroscience
Two very different molecules at the same frontier: a single-session reset that can stop the heart vs a fast, repeatable glutamate antidepressant. Mechanism, evidence, and risk.
DXM (Dextromethorphan): The Neuroscience
The cough-syrup molecule that is also a dissociative and now an FDA-approved antidepressant. Mechanism, the CYP2D6 hinge, Auvelity, the plateaus, and honest risks.
LSD vs DMT: The Neuroscience
Same 5-HT2A doorway, opposite kinetics: the receptor that won't let go vs the molecule gone in minutes. Mechanism, imaging, 2026 trials, and safety.
2C-B: The Neuroscience
Shulgin's phenethylamine between MDMA and LSD: 5-HT2 pharmacology, a steep dose-response, thin-but-growing evidence, and the NBOMe substitution danger.
Ketamine vs Nitrous Oxide: The Neuroscience
Two NMDA antagonists reach the same receptor by an injection and a breath: ketamine, an approved fast rescue with a maintenance problem, versus nitrous oxide, a promising but investigational near-instant candidate.
Kratom (Mitragynine): The Neuroscience
The traditional leaf is a weak, G-protein-biased, multi-target opioid; concentrated 7-OH is a different animal. Mechanism, dependence, hepatotoxicity, and the 2026 leaf/7-OH regulatory split, honestly.
MDMA vs Psilocybin: A Neuroscience Comparison
An empathogen that quiets fear versus a psychedelic that loosens rigidity - how MDMA and psilocybin heal trauma and depression differently, and where each stands in 2026.
Nitrous Oxide Neuroscience: The NMDA Antagonist
Laughing gas is the fastest NMDA antagonist we know: rapid-antidepressant promise, a 175-year clinical record, and the serious B12 nerve damage behind the 2025 surge.
Ketamine vs Psilocybin: A Neuroscience Comparison
Speed versus durability, NMDA versus 5-HT2A - how two rapid-acting antidepressants rewire the depressed brain, compared honestly.
The Neuroscience of THC: How Cannabis Works
A single plant molecule slots into the brain's most abundant receptor network. How THC hijacks the endocannabinoid system, told straight.
Ayahuasca vs Psilocybin: The Neuroscience
Same 5-HT2A receptor, two very different machines. The MAOI dimension, the clinical scoreboard, the safety trade-offs, and the law — side by side.
Salvia Divinorum: The Kappa-Opioid Psychedelic
The only common psychedelic that skips serotonin — salvinorin A hijacks an ancient opioid switch for a brief, reality-fracturing trip.
Psilocybin vs LSD
Same receptor, different molecules — one a natural mushroom, the other a semi-synthetic ergoline 100× more potent. Potency, duration, dose-equivalence, trials, and the law compared.
Amanita Muscaria: The Neuroscience
The world’s most famous mushroom isn’t a psychedelic. Inside the GABA-A chemistry of muscimol and ibotenic acid — effects, toxicity, Siberian myth, and the 2026 legal status.
MDMA vs Ketamine for PTSD
Two drugs, opposite mechanisms — a serotonin flood vs a glutamate surge. The trial evidence head to head, the 2026 regulatory reality, the risks, and which fits whom.
Ibogaine: The Neuroscience
A root-bark alkaloid that interrupts opioid addiction through a long-lived metabolite and GDNF-driven plasticity — shadowed by a lethal cardiac risk. The promise, the mechanism, and the peril.
MDMA: The Neuroscience
Not a classic psychedelic but an empathogen — a serotonin releaser that quiets the amygdala and floods the brain with oxytocin. The PTSD trials, the reopened critical period, and the 2024 FDA rejection.
Mescaline: The Neuroscience
The first psychedelic ever isolated — a cactus alkaloid that opened the 5-HT2A door a century before we knew the receptor. The oldest psychedelic, and the least studied.
Ketamine: The Neuroscience
A 1960s anesthetic that lifts depression in hours by blocking the NMDA receptor — the glutamate surge, the synapses it regrows, and the debate over whether the dissociation is the medicine.
DMT: The Neuroscience
The shortest, strangest trip in pharmacology: it acts in seconds, the body destroys it almost instantly, and the brain itself may make it. The neuroscience of the “spirit molecule.”
LSD: The Neuroscience
Active at a few millionths of a gram, LSD is the most potent classical psychedelic — the 5-HT2A receptor “lid” that traps the molecule and explains the twelve-hour trip, the brain’s dissolved boundaries, and the clinical return through MM120.
Ayahuasca: The Neuroscience of the Vine
Two Amazonian plants, neither psychoactive alone, become one of the most studied psychedelics on Earth — the DMT–MAOI synergy, the quieting of the default mode network, and the rapid-antidepressant trials.
5-MeO-DMT: The Neuroscience of the God Molecule
The most powerful psychedelic acts on a different receptor than all the others — the 5-HT1A mechanism, the fastest ego death, the ultra-rapid antidepressant trials, and the threatened toad behind the molecule.
Psychedelics and Neuroplasticity: Reopening the Brain's Critical Periods
Psychedelics reopen the developmental windows the brain seals after childhood. How a single dose rewires the adult brain — dendritic spines, the TrkB receptor, the reopened critical period — and why what happens next decides everything.
Psychedelics and Meditation: The Contemplative Neuroscience
Two of humanity's oldest technologies for transforming the mind act on the same brain system — the default mode network. How psilocybin and meditation both quiet the self, and what the data show when they are combined.
Psilocybin and Bipolar Disorder: The Field's Hardest Open Question
The first peer-reviewed psilocybin trial that did not exclude bipolar disorder posted MADRS −24 (Cohen d=4.08) and zero hypomanic switches. The exclusion has stood since 2006. The reasoning behind it has not caught up with the data.
Psilocybin and Parkinson's Disease: The Neuroscience of a Possible Disease-Modifying Therapy
The first psychedelic ever tested in a neurodegenerative disease. Bradley 2025 UCSF trial: −9.3 MADRS, −4.6 motor improvement, zero serious adverse events. α-synuclein silences TrkB; psilocin reactivates it. The cleanest disease-modifying logic chain in psychedelic neuroscience.
Veterans and Psilocybin: The Neuroscience of Healing the Wounds of War
22 veterans die by suicide every day. Combat trauma damages four neural systems at once — amygdala, default mode network, fear-extinction circuit, neuroinflammation. Psilocybin is the first intervention demonstrated to engage all four. The full master review on veterans + psilocybin science.
Psilocybin and Alzheimer’s Disease: The Neuroplasticity Hypothesis
BDNF collapses 30–40% in Alzheimer's brains. Psilocybin triggers the largest known BDNF surge. Tau phosphorylation fell ~35% in mouse models. Four mechanisms, one disease — the most unexpected convergence in neurodegeneration research.
The Pineal Gland: Science vs Myth
A pea-sized gland at the geometric center of your brain. Descartes called it the seat of the soul. Strassman called it the DMT factory. Borjigin's lab found DMT-producing enzymes everywhere — not just the pineal. The myth, the data, and the truth in between.
5-MeO-DMT vs Psilocybin: Two Doors to the Same Room
Six hours vs fifteen minutes. Davis (2018) showed 5-MeO-DMT mystical intensity equals high-dose psilocybin. GH001 hit -15.5 MADRS in Phase 2b TRD. The pharmacology, phenomenology, and clinical data on two doors into the same room.
Psilocybin and Nicotine Addiction: How a Single Session Breaks the Hardest Habit
80% quit rate after 2-3 sessions vs 13% for nicotine patches. Johns Hopkins researchers have cracked the neuroscience of tobacco addiction — and it starts with the default mode network.
Psilocybin and Anxiety: The Neuroscience of Dissolving Fear
80% of participants reported sustained anxiety relief after a single psilocybin session. The amygdala quiets, the default mode network resets, and fear patterns built over decades dissolve.
Psilocybin and Neurogenesis: How Psychedelics Grow New Brain Cells
The adult brain was supposed to stop growing new neurons. Psilocybin proved otherwise. Hippocampal neurogenesis surges after a single dose — the biological mechanism behind the antidepressant effect.
Precision-dosed psilocybin
mushroom products.
Engineered for daily ritual, neural reconstruction, and sustained cognitive performance. Lab-tested. Ceremony-ready.
SHOP OOTW MUSHROOM PRODUCTSAbout Out Of This World
We operate at the threshold where ancient plant wisdom meets modern clinical observation. OOTW JOURNAL exists because psilocybin science deserves a dedicated platform — one that treats the research with the seriousness it demands. No hype. No speculation. Only mechanisms, clinical data, and protocols.
Our primary focus is psilocybin: receptor pharmacology, neuroplasticity, BDNF expression, veteran restoration, daily microdosing protocols. We also cover adjacent psychedelic compounds and consciousness research. New articles published daily. Every claim backed by peer-reviewed data.
Shop OOTW Mushroom Products open_in_new